Tag: Tessa Munt

The below Parliamentary question was asked by Tessa Munt on 2014-07-15.

To ask the Secretary of State for Health, if he will request NHS England to authorise the use of Gamma Knife for NHS patients at University College Hospital London.

Jane Ellison

NHS England is an independent arm’s length body and since 1 April 2013, it has been responsible for commissioning all radiotherapy services, including stereotactic radiosurgery. Gamma Knife treatment has been available to all patients who meet clinical criteria, without the need for individual funding requests, under NHS England’s national clinical commissioning policies for specialised services.

University College London Hospitals is not contracted by NHS England, nor was it contracted by former primary care trusts, to provide Gamma Knife services. It is for this reason that National Health Service patients cannot normally be treated at this facility. Instead, NHS patients requiring Gamma Knife treatment should be treated by the Gamma Knife services commissioned by the NHS, that have been shown to meet NHS England service specifications. These can be accessed by patients in London without a waiting time, fully maintaining the continuity of their care and normally with the same consultant and clinical team.

All patients need to be treated in accordance with the prescribed clinical pathways and in line with contractual agreements with providers.

The below Parliamentary question was asked by Tessa Munt on 2014-07-15.

To ask the Secretary of State for Health, for what reason none of the £42 million his Department has made available for increasing the use of radiotherapy is to be spent on treating cancer patients with Stereotactic Ablative Radiotherapy this year.

Jane Ellison

In July 2011, the National Radiotherapy Implementation Group concluded that current evidence supports treatment withstereotactic ablative radiotherapy (SABR) for only a small number of patients. The evidence supports its use in the treatment of early stage lung cancers for patients who are unsuitable for surgery (approximately 1,000 per annum).

NHS England recognises the positive clinical impact that its national policy on SABR for the treatment of early non-small cell lung cancer has had. It is currently examining the potential use of SABR in patients with oligometastatic disease – where a cancer is in the early stages of spreading.

NHS England is also currently undertaking a review of stereotactic radiosurgery (SRS) and SABR for intracranial conditions to establish what the national demand is in line with its national clinical commissioning policies on SRS and SABR, and what the national capacity requirements are for this specialised treatment. Following the review it is planned that a final decision will be taken by the Specialised Commissioning Oversight Group in October 2014.

Later this year, the Radiotherapy Clinical Reference Group will review its current policy position on SABR to assess whether there is new evidence to recommend its use on other conditions. It is important to ensure that treatments commissioned are supported by robust evidence of their benefit to patients.

The below Parliamentary question was asked by Tessa Munt on 2014-07-15.

To ask the Secretary of State for Health, how many individual funding requests per indication were received by NHS England for radiotherapy treatment in the last financial year; and how many requests, per indication, were refused by NHS England.

Norman Lamb

Since April 2013, radiotherapy treatment has been planned and paid for nationally by NHS England.

NHS England has informed us that information on the number of individual funding requests made to NHS England is not currently available. NHS England is improving its data collection mechanisms and aims to improve availability of such information in the future.

The below Parliamentary question was asked by Tessa Munt on 2014-07-15.

To ask the Secretary of State for Health, for what reasons NHS England is instructing hospitals with patients presenting as clinically urgent to treat such patients with innovative radiotherapy at the hospital’s financial risk while it decides whether to fund the patient; and how hospitals which have followed that instruction receive reimbursement for that expenditure if NHS England subsequently refuses to fund the treatment.

Jane Ellison

NHS England is an independent arm’s length body and since 1 April 2013, it has been responsible for commissioning all radiotherapy services, including stereotactic radiosurgery. Gamma Knife treatment has been available to all patients who meet clinical criteria, without the need for individual funding requests, under NHS England’s national clinical commissioning policies for specialised services.

University College London Hospitals is not contracted by NHS England, nor was it contracted by former primary care trusts, to provide Gamma Knife services. It is for this reason that National Health Service patients cannot normally be treated at this facility. Instead, NHS patients requiring Gamma Knife treatment should be treated by the Gamma Knife services commissioned by the NHS, that have been shown to meet NHS England service specifications. These can be accessed by patients in London without a waiting time, fully maintaining the continuity of their care and normally with the same consultant and clinical team.

All patients need to be treated in accordance with the prescribed clinical pathways and in line with contractual agreements with providers.

The below Parliamentary question was asked by Tessa Munt on 2014-07-15.

To ask the Secretary of State for Health, to what extent NHS England is obliged to follow guidance issued by Monitor.

Jane Ellison

It is the National Health Service (Procurement, Patient Choice and Competition) (No. 2) Regulations 2013 that place requirements on NHS England, including requirements as to good practice in relation to procurement.

Enforcement of the procurement requirements by Monitor may only follow its investigation of a complaint that there has been a failure by a commissioner to comply with the requirements. Monitor has published guidance for NHS England and other commissioners of healthcare services which provides advice on how to comply with the regulations. Monitor expects to follow the interpretation of the regulations that it has set out in its guidance when exercising its enforcement powers under the regulations.

In addition, to the extent that NHS England acts as a commissioner of services, it has a legal duty to have regard to guidance which Monitor publishes for commissioners of services which are designated as ‘commissioner requested services’. Before publishing the guidance or any revisions to it, Monitor must have first consulted NHS England.

The below Parliamentary question was asked by Tessa Munt on 2015-02-12.

To ask the Secretary of State for Work and Pensions, how many individual cold weather payments were made to recipients in the UK in winter 2013-14.

Steve Webb

Only one trigger was recorded in the 2013/14 Cold Weather season and an estimated 1,100 payments paid. Further details can be found in the ‘Social Fund Cold Weather Payments for Great Britain from 1st November 2013 to 31st March 2014’ update on Gov.uk which may be found at

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/299461/sf-cwp-31-03-2014.pdf.

“

The below Parliamentary question was asked by Tessa Munt on 2015-02-12.

To ask the Secretary of State for Work and Pensions, how many recipients of UK state pension reside in the French overseas department of (a) Guiana, (b) Martinique, (c) Guadeloupe and (d) Reunion.

Steve Webb

Information on the number of recipients of UK state pension residing in France, and of those how many are in the French Overseas Departments, is available at: http://tabulation-tool.dwp.gov.uk/100pc/sp/cccountry/cnage/a_carate_r_cccountry_c_cnage_may14.html

“

The below Parliamentary question was asked by Tessa Munt on 2015-02-12.

To ask the Secretary of State for Work and Pensions, how many recipients of UK state pension reside in metropolitan France.

Steve Webb

Information on the number of recipients of UK state pension residing in France, and of those how many are in the French Overseas Departments, is available at: http://tabulation-tool.dwp.gov.uk/100pc/sp/cccountry/cnage/a_carate_r_cccountry_c_cnage_may14.html

“

The below Parliamentary question was asked by Tessa Munt on 2014-04-30.

To ask the Secretary of State for Health, what progress NHS England is making on improving access to stereotactic ablative radiotherapy for patients suffering with cancer of the prostate, liver, pancreas, spinal tumours and cancer of the head and neck.

Jane Ellison

The business case for the gamma-knife centre at Oxford was originally agreed with the primary care trust (PCT) prior to April 2013, with an assumption that the PCT would stop sending patients to other centres elsewhere, and start sending them to the new centre once it was completed.

As of April 2013, commissioning of these services transferred to the specialist commissioning team in NHS England.

NHS England is currently undertaking a review of stereotactic radiosurgery (SRS) (e.g. Gamma Knife) and stereotactic ablative radiotherapy (SABR, e.g. Cyber-knife) for intracranial conditions to establish what the national demand is in line with its national clinical commissioning policies on SRS and SABR, and what the national capacity requirements are for this specialised treatment.

Until the capacity requirements are clear, NHS England has said that it would be inappropriate to encourage new market entrants to provide this service as it cannot be clear what the potential consequential impacts on service quality, sustainability (financial and clinical) and potential unintended changes to patient pathways will be. Until the review is complete NHS England has said no substantive changes will be made to the current provision.

As part of the transition of this service to NHS England, it developed, consulted upon and published a series of national clinical commissioning policies for intracranial SRS and SRT treatment.

A report setting out the emerging findings of this review has been shared with clinical reference groups to seek their views and help NHS England develop a final draft. Once the views of stakeholders have been gathered, this will then go to Specialised Commissioning Oversight Group (SCOG) to agree a preferred option. Once the SCOG has a preferred option, NHS England will consult with patients and professionals and take account of those views when taking a final decision. If it is concluded there are to be significant changes in the provision of services, there will be a full public consultation before any changes are made.

NHS England is expecting that the draft report will be ready for consideration at SCOG in June and then it would commence a public consultation on the draft report and preferred option during July to September. The report and recommendations will then be finalised after taking account of the views expressed during the consultation stage and a final decision taken by SCOG in September 2014.

NHS England inherited the range of gamma knife providers currently in place, of which University College London Hospitals (UCLH) was not one. NHS England is currently undertaking a review of stereotactic radiosurgery provision and will consult widely with stakeholders and providers prior to making changes to service provision. There are two long established providers of gamma knife surgery commissioned by NHS England located in central London to whom patients from all six London specialist neurosurgical centres have been referred for gamma knife treatment for a number of years, including patients from UCLH.

Finally, there was no contract in place with UCLH to provide gamma knife surgery for any PCT prior to 1 April 2013. Any activity that may have been undertaken there would have been done on an ad-hoc, non-contracted basis and NHS England does not hold this information.

The below Parliamentary question was asked by Tessa Munt on 2014-04-30.

To ask the Secretary of State for Health, if he will take steps to encourage NHS England to respond to the Oxford Radiosurgery Centre’s request that NHS patients in Oxfordshire and surrounding counties who require radiosurgery be treated there.

Jane Ellison

The business case for the gamma-knife centre at Oxford was originally agreed with the primary care trust (PCT) prior to April 2013, with an assumption that the PCT would stop sending patients to other centres elsewhere, and start sending them to the new centre once it was completed.

As of April 2013, commissioning of these services transferred to the specialist commissioning team in NHS England.

NHS England is currently undertaking a review of stereotactic radiosurgery (SRS) (e.g. Gamma Knife) and stereotactic ablative radiotherapy (SABR, e.g. Cyber-knife) for intracranial conditions to establish what the national demand is in line with its national clinical commissioning policies on SRS and SABR, and what the national capacity requirements are for this specialised treatment.

Until the capacity requirements are clear, NHS England has said that it would be inappropriate to encourage new market entrants to provide this service as it cannot be clear what the potential consequential impacts on service quality, sustainability (financial and clinical) and potential unintended changes to patient pathways will be. Until the review is complete NHS England has said no substantive changes will be made to the current provision.

As part of the transition of this service to NHS England, it developed, consulted upon and published a series of national clinical commissioning policies for intracranial SRS and SRT treatment.

A report setting out the emerging findings of this review has been shared with clinical reference groups to seek their views and help NHS England develop a final draft. Once the views of stakeholders have been gathered, this will then go to Specialised Commissioning Oversight Group (SCOG) to agree a preferred option. Once the SCOG has a preferred option, NHS England will consult with patients and professionals and take account of those views when taking a final decision. If it is concluded there are to be significant changes in the provision of services, there will be a full public consultation before any changes are made.

NHS England is expecting that the draft report will be ready for consideration at SCOG in June and then it would commence a public consultation on the draft report and preferred option during July to September. The report and recommendations will then be finalised after taking account of the views expressed during the consultation stage and a final decision taken by SCOG in September 2014.

NHS England inherited the range of gamma knife providers currently in place, of which University College London Hospitals (UCLH) was not one. NHS England is currently undertaking a review of stereotactic radiosurgery provision and will consult widely with stakeholders and providers prior to making changes to service provision. There are two long established providers of gamma knife surgery commissioned by NHS England located in central London to whom patients from all six London specialist neurosurgical centres have been referred for gamma knife treatment for a number of years, including patients from UCLH.

Finally, there was no contract in place with UCLH to provide gamma knife surgery for any PCT prior to 1 April 2013. Any activity that may have been undertaken there would have been done on an ad-hoc, non-contracted basis and NHS England does not hold this information.